TESARO, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-03-01
- Employees
- 715
- Market Cap
- -
- Website
- http://tesarobio.com
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03307785
- Locations
- 🇺🇸
GSK Investigational Site, San Marcos, Texas, United States
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT03250832
- Locations
- 🇫🇷
GSK Investigational Site, Villejuif cedex, France
Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Tesaro, Inc.
- Registration Number
- NCT03025867
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT02817633
- Locations
- 🇨🇳
GSK Investigational Site, Tainan, Taiwan
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 740
- Registration Number
- NCT02715284
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02657889
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 733
- Registration Number
- NCT02655016
- Locations
- 🇬🇧
GSK Investigational Site, Truro, United Kingdom
Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02476552
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02434861
- Locations
- 🇺🇸
Parexel Early Phase Unit, Baltimor, Maryland, United States
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02382666
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath